Tumor-associated calcium signal transducer

China's first personalized neoantigen-targeted cancer vaccine receives NMPA's clinical trial approval

Retrieved on: 
Friday, March 17, 2023

This is the first personalized neoantigen vaccine & mRNA editing product approved by the NMPA to enter clinical stage.

Key Points: 
  • This is the first personalized neoantigen vaccine & mRNA editing product approved by the NMPA to enter clinical stage.
  • LK101 Injection, the first in-house developed cancer vaccine candidates by Likang, is a personalized neoantigen-targeted cancer vaccine and also a dendritic cell (DC)-based mRNA vaccine that combines advantages of both mRNA technology and DC by transducing mRNA encoding personalized tumor antigen targets based on dozens of patient-specific tumor mutations information into dendritic cells.
  • The combination of mRNA vaccine and DC vaccine provides a potential breakthrough in the field of personalized neoantigen treatment, offering an effective and safe approach for patients to fight against cancer.
  • In 2018, Likang collaborated with the Chinese PLA General Hospital to conduct an investigator-initiated clinical trial (IIT) of LK101 injection for postoperative liver cancer patients.

China's first personalized neoantigen-targeted cancer vaccine receives NMPA's clinical trial approval

Retrieved on: 
Friday, March 17, 2023

This is the first personalized neoantigen vaccine & mRNA editing product approved by the NMPA to enter clinical stage.

Key Points: 
  • This is the first personalized neoantigen vaccine & mRNA editing product approved by the NMPA to enter clinical stage.
  • LK101 Injection, the first in-house developed cancer vaccine candidates by Likang, is a personalized neoantigen-targeted cancer vaccine and also a dendritic cell (DC)-based mRNA vaccine that combines advantages of both mRNA technology and DC by transducing mRNA encoding personalized tumor antigen targets based on dozens of patient-specific tumor mutations information into dendritic cells.
  • The combination of mRNA vaccine and DC vaccine provides a potential breakthrough in the field of personalized neoantigen treatment, offering an effective and safe approach for patients to fight against cancer.
  • In 2018, Likang collaborated with the Chinese PLA General Hospital to conduct an investigator-initiated clinical trial (IIT) of LK101 injection for postoperative liver cancer patients.